FCCC LOGO Faculty Publications
Peters ME , Shareef MM , Gupta S , Zagurovskaya-Sultanov M , Kadhim M , Mohiuddin M , Ahmed MM
Potential utilization of bystander/abscopal-mediated signal transduction events in the treatment of solid tumors
Current Signal Transduction Therapy. 2007 May;2(2) :129-143
PMID: ISI:000246490000004   
Back to previous list
Abstract
A transformed cell among a group of normal cells exerts a dynamic influence for clonal growth and mass transformation. Likewise, a treatment-induced damaged cell might exert deleterious signal to either neighboring or distal cells. These signals that elicit either transformation or cell death are classified under two independent phenomena. These two phenomena are called (1) Abscopal effect and (2) Bystander effect. There are several agents that have been reported to induce abscopal and bystander effects. Ionizing radiation and ultraviolet radiation are prime inducers of abscopal and bystander effects. In addition, localized therapies for tumor control such as gene therapy approaches, prodrug conversion based chemotherapy approaches, and surgical procedures are significant inducers of either abscopal or bystander effects. The proposed mechanisms that have been reported in literature clearly indicate pivotal roles of cytokine and ceramide signaling leading to the activation of pro-survival proteins and/or pro-apoptotic proteins. Together these pathways provide distinct differences between abscopal and bystander effects that are of particular interest in modem cancer therapeutics. The most exciting future direction of bystander/abscopal biology in terms of cancer therapeutics will potentially arise from the use of stem cells. In this review, a critical evaluation of potential benefits of abscopal/bystander effects mediated signaling pathways in relation to cancer therapeutics are discussed in detail.
Notes
ISI Document Delivery No.: 167YY Times Cited: 0 Cited Reference Count: 155 Cited References: AGARD C, 2001, CANCER GENE THER, V8, P128 AHMED MM, 2004, CURR CANCER DRUG TAR, V4, P43 ALBANESE J, 2000, RADIAT RES, V154, P616 AZZAM EI, 1992, LOW DOSE IRRADIATION, P291 AZZAM EI, 2001, P NATL ACAD SCI USA, V98, P473 AZZAM EI, 2003, ONCOGENE, V22, P7050 AZZAM EI, 2004, CURR CANCER DRUG TAR, V4, P53 AZZAM EI, 2004, HUM EXP TOXICOL, V23, P61 BAI SC, 1999, BIOCHEM BIOPH RES CO, V259, P455 BANERJEE G, 2005, CANCER LETT, V223, P275 BARTL MM, 2001, EXP CELL RES, V271, P130 BEVAN MJ, 1976, J EXP MED, V143, P1283 BIROCCIO A, 2005, J CELL PHYSIOL, V204, P463 CAMPHAUSEN K, 2003, CANCER RES, V63, P1990 CAUDELL EG, 2002, J IMMUNOL, V168, P6041 CHADA S, 2004, MOL THER, V10, P1085 CHAKRAVARTY PK, 1999, CANCER RES, V59, P6028 CHHIKARA M, 2001, MOL THER, V3, P536 COFFEY JC, 2005, J BIOL CHEM, V280, P20968 CRISWELL T, 2003, CANCER BIOL THER, V2, P372 CULVER KW, 1992, SCIENCE, V256, P1550 CUNI S, 2004, LEUKEMIA, V18, P1391 CURIEL DT, 1996, CANC BIOTECHNOLOGY W, P22 DAHLE J, 2000, BBA-GEN SUBJECTS, V1475, P273 DAHLE J, 2000, RADIAT RES, V154, P331 DAHLE J, 2001, PHOTOCHEM PHOTOBIOL, V73, P378 DAINIAK N, 2002, EXP HEMATOL, V30, P513 DANCEY JE, 2004, ANN ONCOL S4, V15, P233 DAS A, 2001, J BIOL CHEM, V276, P3279 DAVIDOFF AM, 2001, CLIN CANCER RES, V7, P2870 DEMARIA S, 2004, INT J RADIAT ONCOL, V58, P862 DEMARTIS A, 1996, CANCER RES, V56, P4213 DENNY WA, 2004, CANCER INVEST, V22, P604 DUBBEN HH, 1998, RADIOTHER ONCOL, V47, P167 ELLERHORST JA, 2002, J CLIN ONCOL, V20, P1069 FLEMING AB, 2002, CLIN PHARMACOKINET, V41, P403 FORRESTER K, 1996, P NATL ACAD SCI USA, V93, P2442 FORSTERMANN U, 1990, BIOCHEM BIOPH RES CO, V168, P727 FREEMAN SM, 1993, CANCER RES, V53, P5274 FU MG, 2003, GENE, V315, P33 FUJIWARA T, 2000, MOL UROL, V4, P51 GANSAUGE S, 1998, CELL GROWTH DIFFER, V9, P611 GERA JF, 2004, J BIOL CHEM, V279, P2737 GIESE A, 2004, J NEURO-ONCOL, V66, P351 GLEAVE M, 2005, WORLD J UROL, V23, P38 GLEAVE ME, 2001, UROLOGY S, V58, P39 GOLDBERG Z, 2002, INT J ONCOL, V21, P337 GOTLIEB WH, 1994, AM J OBSTET GYNECOL, V170, P1121 GRUNWALD V, 2002, CANCER RES, V62, P6141 GURURANGAN S, 2001, NEURO-ONCOLOGY, V3, P246 HALLAHAN DE, 1995, NAT MED, V1, P786 HALPERN BC, 1974, P NATL ACAD SCI USA, V71, P1133 HARRISON LH, 2000, ANN THORAC SURG, V70, P407 HOLMGREN L, 1995, NAT MED, V1, P149 HONG JS, 2004, CANCER RES, V64, P6610 HOSOI H, 1998, MOL PHARMACOL, V54, P815 HUANG AYC, 1994, SCIENCE, V264, P961 HUANG G, 2003, SICHUAN DA XUE XUE B, V34, P51 HUANG S, 2001, DRUG RESIST UPDATE, V4, P378 HUANG XF, 2003, INT J ONCOL, V22, P1241 IBUKI Y, 1998, BIOL PHARM BULL, V21, P434 IKEDA M, 2002, GASTRIC CANC, V5, P137 ISHIKAWA H, 2003, LEUKEMIA LYMPHOMA, V44, P1477 IYER R, 2000, CANCER RES, V60, P1290 IYER R, 2002, MUTAT RES-FUND MOL M, V503, P1 IYER R, 2002, RADIAT RES, V157, P3 JIANG HP, 1996, P NATL ACAD SCI USA, V93, P9160 JIN G, 1999, EUR J BIOCHEM, V263, P534 KADHIM MA, 2004, MUTAT RES-FUND MOL M, V568, P21 KAMINSKI JM, 2005, CANCER TREAT REV, V31, P159 KIANMANESH AR, 1997, HUM GENE THER, V8, P1807 KINGSLEY DPE, 1975, BRIT J RADIOL, V48, P863 KLOKOV D, 2004, MUTAT RES-FUND MOL M, V568, P97 KOKKINAKIS DM, 2004, CANCER RES, V64, P7513 KOUNNAS MZ, 1995, J BIOL CHEM, V270, P13070 LIANG L, 2002, MUTAT RES-FUND MOL M, V502, P69 LIEBMANN J, 1994, CANCER RES, V54, P3365 LIMOLI CL, 2003, NEOPLASIA, V5, P339 LIN PN, 1998, CELL GROWTH DIFFER, V9, P49 LITTLE JB, 2003, ONCOGENE, V22, P6978 LYNG FM, 2002, RADIAT PROT DOSIM, V99, P169 LYNG FM, 2002, RADIAT RES, V157, P365 MAGUIRE P, 2005, RADIAT RES, V163, P384 MALYSHEV IY, 1995, FEBS LETT, V370, P159 MANIWA Y, 1998, CHEST, V114, P1668 MANOME Y, 1996, AIDS WEEKLY PLUS MARASKOVSKY E, 1996, J EXP MED, V184, P1953 MATSUMOTO H, 1995, CANCER LETT, V92, P127 MATSUMOTO H, 2001, RADIAT RES, V155, P387 MATTHEWS T, 1988, REV INFECT DIS, V10, P490 MELIEF CJM, 1992, ADV CANCER RES, V58, P143 MENG FM, 2005, AM J PHYSIOL-CELL PH, V289, C971 MHASHILKAR AM, 2001, MOL MED, V7, P271 MIKI S, 1989, FEBS LETT, V250, P607 MILLAUER B, 1994, NATURE, V367, P576 MIYAKE H, 2004, J UROLOGY 1, V171, P2477 MIZUTANI Y, 1995, CANCER RES, V55, P590 MOHIUDDIN M, 1999, INT J RADIAT ONCOL, V45, P721 MORAN DM, 2005, LIVER INT, V25, P445 MORGAN WF, 2003, RADIAT RES, V159, P581 MOSS RW, 2003, TOWNSEND LETT DOCTOR MOTHERSILL C, 1998, RADIAT RES, V149, P256 MOTHERSILL C, 2002, RADIAT RES, V158, P626 MOTHERSILL CE, 2004, INT J RADIAT ONCOL, V58, P575 NAGAR S, 2005, RADIAT RES, V163, P316 NAGASAWA H, 1992, CANCER RES, V52, P6394 NICULESCUDUVAZ I, 2005, MOL BIOTECHNOL, V30, P71 NIKJOO H, 2004, HUM EXP TOXICOL, V23, P81 NISHIKAWA T, 2004, MOL THER, V9, P818 NOBLER MP, 1969, RADIOLOGY, V93, P410 NORRIS JS, 2001, CURR GENE THER, V1, P123 OHTSUBO T, 1997, CANCER RES, V57, P3910 OLEKSOWICZ L, 1995, MED ONCOL, V12, P95 PAN X, 2002, CHINESE MED J-PEKING, V115, P1205 PATTERSON AV, 2003, CURR PHARM DESIGN, V9, P2131 PIDGEON GP, 1999, BRIT J CANCER, V81, P1311 PRESTON RJ, 2005, TOXICOL APPL PHARM, V207, P550 RAMESH R, 2003, CANCER RES, V63, P5105 REARDON JE, 1989, J BIOL CHEM, V264, P19039 REES GJG, 1983, BRIT J RADIOL, V56, P63 SANCHEZORTIZ RF, 2003, J UROLOGY, V170, P178 SARKAR D, 2002, P NATL ACAD SCI USA, V99, P10054 SATHISHKUMAR S, 2002, TECHNOL CANCER RES T, V1, P141 SATHISHKUMAR S, 2005, CANCER BIOL THER, V4, P979 SAWANT SG, 2002, RADIAT RES, V157, P361 SHAM RL, 1995, AM J MED, V98, P307 SHAO C, 2002, INT J RADIAT BIOL, V78, P837 SHAO C, 2005, INT J CANCER, V116, P45 SHAO CL, 2004, P NATL ACAD SCI USA, V101, P13495 SHAREEF MM, 2004, CANCER BIOL THER, V3, P752 SHI YF, 1995, CANCER RES, V55, P1982 SHIN I, 2001, MOL BIOL CELL, V12, P3328 SNYDER AR, 2004, HUM EXP TOXICOL, V23, P87 STABA MJ, 1998, GENE THER, V5, P293 STEFANI AL, 2005, J HEPATOL, V42, P728 TASSONE P, 2005, CLIN CANCER RES, V11, P4251 TEH B, 2002, ONCOLOGIST, V7, P458 THUST R, 1996, ANTIVIR RES, V31, P105 VALDES F, 2004, EXP CELL RES, V292, P209 VANDERMEEREN A, 2005, RADIAT RES, V163, P144 VANDILLEN IJ, 2002, CURR GENE THER, V2, P307 VINALS F, 2001, MOL CELL BIOL, V21, P7218 WALDREN CA, 2004, HUM EXP TOXICOL, V23, P95 WANG AX, 2003, ZHONGHUA KOU QIANG Y, V38, P24 WEI JW, 2004, CANCER CELL, V5, P477 WILSON DN, 2002, CURR PROTEIN PEPT SC, V3, P1 WORKMAN P, 2003, CURR CANCER DRUG TAR, V3, P297 WRIGHT EG, 2004, HUM EXP TOXICOL, V23, P91 YACOUB A, 2004, CANCER BIOL THER, V3, P739 YAMANAKA K, 2005, MOL CANCER THER, V4, P187 YANG CR, 2000, P NATL ACAD SCI USA, V97, P5907 ZELLWEGER T, 2001, NEOPLASIA, V3, P360 ZHANG A, 2004, J HUAZHONG U SCI TEC, V24, P476 ZHANG XM, 2002, CHIN J GEN SURG, V17, P22 ZHOU HN, 2000, P NATL ACAD SCI USA, V97, P2099